3 potentially overvalued FTSE stocks I’d still consider buying on a dip

Some recent stock market successes for UK companies have resulted in over-inflated stock prices. I look at three worth watching in 2020.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While worldwide worries have prevented many stocks from thriving in 2019, a select few have defied expectations and done extremely well. Positive sentiment drives buyers to these stocks, but it can also result in them becoming overvalued, when they become too expensive for their own good.

I think this is the case for several such successes in recent months, but there are still a few I’d take my chances with, particularly if the share price drops.

From the FTSE 100, I’d choose global pharmaceutical giant Astrazeneca (LSE:AZN), while from the FTSE 250, I’d choose Future (LSE:FUTR), an international media group and digital publisher, and JD Sports Fashion, the sports retailer.

Health for wealth

Astrazeneca has had an exceptionally good year. Its share price has risen over 27% since January.  This is thanks to several positive developments in its drug research and commercialisation.

It specialises in the treatment of diseases in the areas of oncology, cardiovascular, renal and metabolism, and respiratory.

November alone was impressive. Its drug Imfinzi was granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer, an aggressive, fast-growing form of lung cancer. Calquence, a leukaemia drug, was approved in the US for adult patients, Qtrilmet was approved in the EU for the treatment of type-2 diabetes, and the FDA accepted a New Drug Application and granted Priority Review for Selumetinib, as a potential new medicine for paediatric patients with NF1, a rare and incurable genetic condition.

This pharma favourite has a trailing price-to-earnings ratio (P/E) of 47 and its dividend yield is 2.9%. Earnings per share are £1.31 and its debt ratio is 68%.

Future returns

Customer loyalty has contributed to record revenue growth for Future and according to the London Stock Exchange, its e-commerce clicks soared 44% year-on-year following Black Friday 2019.

This publishing giant’s top online properties include technology sites TechRadar, GamesRadar, and Tom’s Guide. Leading products advertised and sold through these sites on Black Friday included Google’s Pixel 4 smartphone, and the Sony Playstation VR, as well as subscriptions to streaming services such as Hulu and Disney+.

The relevance and trusted nature of these sites give consumers the confidence to shop online as the sites offer expert buying advice across consumer categories such as tech, games, music, homes, and more.

Future has recently announced two major acquisitions; a £140m acquisition of TI Media, a UK-based print-let consumer magazine and digital publisher with brands such as Marie Claire and World Soccer. This preceded the £23.5m acquisition of Barcroft Studios, creator of digital video and television content.

Future has an astronomical trailing P/E of 138. Its dividend yield is a very low 0.14% but the cover is more than 10 times. Earnings per share are 9p and its debt ratio is a low 12%.

Sporting hero

JD Sports Fashion has a P/E of 28, so not as high as the previous two. Its dividend yield is a very low 0.22% but it has a dividend cover of 15 times, which means it could increase if the company continues to thrive. Earnings per share are 26p.

It’s important to note that these stocks are currently overvalued, so I think they’re worth watching for the possibility to buy on a dip, but I wouldn’t rush out and buy them at today’s prices.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

In volatile markets, could National Grid dividends be a safe haven?

National Grid offers a dividend yield well above the FTSE 100 and aims to keep growing its payout per share.…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

Down 25%, are Barclays shares simply too cheap to ignore?

Barclays shares have given up a chunk of their recent gains since the Middle East powder keg ignited. Should investors…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

How much would someone need in an ISA to target a £1,000 monthly second income?

Christopher Ruane explains how someone could use an empty Stocks and Shares ISA to target a four-figure monthly second income…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Are investors taking a big gamble chasing Rolls-Royce shares higher and higher?

With Rolls-Royce shares having fallen back from their peak, the temptation to see this as a buying opportunity must be…

Read more »

Cargo containers with European Union and British flags reflecting Brexit and restrictions in export and import
Investing Articles

Down 70%, is Fevertree Drinks a share to consider buying at 815p?

Fevertree reported its 2025 earnings today and the investors liked what they saw. So is this a share to consider…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Stock market correction: a once-in-a-decade opportunity to get rich?

Harvey Jones examines whether investors should take advantage of the current stock market correction to buy bargain-priced FTSE 100 shares.

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

Down 15% and a yield of 7.9%! Is this REIT dividend champion now irresistible?

This real estate investment trust (REIT) has one of the highest dividend yields on the London Stock Market. Royston Wild…

Read more »

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

Down 32% and with a P/E of 9.5, is this FTSE 250 share too cheap to ignore?

This FTSE 250 share is in freefall after slashing guidance for this financial year. But Royston Wild eyes a potential…

Read more »